Brainstorm Cell Therapeut... (BCLI)
NASDAQ: BCLI
· Real-Time Price · USD
0.63
0.03 (5.00%)
At close: Aug 15, 2025, 2:51 PM
Brainstorm Cell Therapeutics Income Statement
Financials in USD. Fiscal
year is
January - December.
| Fiscal Year | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 | Q2 2022 | Q1 2022 | Q4 2021 | Q3 2021 | Q2 2021 | Q1 2021 |
| Period Ending | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 |
Revenue | n/a | n/a | n/a | n/a | n/a | 343K | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Cost of Revenue | n/a | n/a | n/a | n/a | 64K | 66K | 65K | n/a | n/a | 70K | n/a | n/a | n/a | 70K | 67K | n/a | n/a |
Gross Profit | n/a | n/a | n/a | n/a | -633K | 277K | -65K | n/a | n/a | -70K | n/a | n/a | n/a | -70K | -67K | n/a | n/a |
Operating Income | -3.09M | -3.19M | -3.05M | -2.98M | -2.47M | -4.8M | -6.04M | -5.45M | -5.15M | -4.92M | -6.84M | -7.59M | -5.47M | -6.21M | -5.28M | -6.12M | -6.93M |
Interest Income | 46K | n/a | n/a | 30K | 13K | -92.12K | n/a | 120K | 92K | n/a | n/a | n/a | 115K | 22K | n/a | n/a | 267K |
Pretax Income | -2.86M | -2.97M | -2.71M | -2.54M | -3.4M | -5.58M | -1.23M | -5.33M | -5.06M | -5.02M | -6.86M | -7.04M | -5.36M | -6.19M | -5.34M | -6.27M | -6.66M |
Net Income | -2.86M | -2.97M | -2.71M | -2.54M | -3.4M | -5.58M | -1.23M | -5.33M | -5.06M | -5.02M | -6.86M | -7.04M | -5.36M | -6.19M | -5.34M | -6.27M | -6.66M |
Selling & General & Admin | 1.78M | 1.47M | 2M | 2.06M | 1.51M | 3.11M | 2.71M | 2.65M | 2.23M | 2.46M | 3.06M | 2.48M | 2.86M | 2.54M | 1.66M | 2.52M | 2.59M |
Research & Development | 1.3M | 1.67M | 1.04M | 922K | 897K | 1.7M | 3.33M | 2.79M | 2.92M | 2.45M | 3.78M | 5.11M | 2.62M | 3.68M | 3.62M | 3.6M | 4.34M |
Other Expenses | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Operating Expenses | 3.09M | 3.19M | 3.05M | 2.98M | 2.41M | 4.8M | 6.04M | 5.45M | 5.15M | 4.92M | 6.84M | 7.59M | 5.47M | 6.21M | 5.28M | 6.12M | 6.93M |
Interest Expense | n/a | n/a | n/a | n/a | n/a | 92K | n/a | n/a | n/a | 103K | n/a | n/a | n/a | n/a | 59K | n/a | n/a |
Selling & Marketing Expenses | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Cost & Expenses | 3.09M | 3.19M | 3.05M | 2.98M | 2.47M | 4.8M | 6.04M | 5.45M | 5.15M | 4.92M | 6.84M | 7.59M | 5.47M | 6.21M | 5.28M | 6.12M | 6.93M |
Income Tax Expense | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Shares Outstanding (Basic) | 6.34M | 5.71M | 5.31M | 4.75M | 4.32M | 3.36M | 2.95M | 2.65M | 2.45M | 2.44M | 2.43M | 2.43M | 2.43M | 2.42M | 2.42M | 2.42M | 2.39M |
Shares Outstanding (Diluted) | 6.34M | 5.71M | 5.31M | 4.75M | 4.32M | 3.36M | 2.95M | 2.65M | 2.45M | 2.44M | 2.43M | 2.43M | 2.43M | 2.42M | 2.42M | 2.42M | 2.39M |
EPS (Basic) | -0.45 | -0.56 | -0.51 | -0.54 | -0.75 | -0.11 | -0.45 | -1.95 | -0.13 | -0.14 | -2.85 | -2.85 | -2.25 | -0.17 | -2.25 | -2.55 | -2.85 |
EPS (Diluted) | -0.45 | -0.56 | -0.51 | -0.54 | -0.75 | -0.11 | -0.45 | -1.95 | -2.1 | -0.14 | -2.85 | -2.85 | -2.25 | -0.17 | -2.25 | -2.55 | -2.85 |
EBITDA | -3.04M | -3.14M | -2.99M | -2.92M | -2.41M | -5.51M | -5.97M | -5.38M | -5.08M | -4.84M | -6.77M | -7.52M | -5.4M | -6.14M | -5.21M | -6.06M | -6.87M |
EBIT | -3.09M | -3.19M | -3.05M | -2.98M | -2.47M | -5.58M | -6.04M | -5.45M | -5.15M | -4.92M | -6.84M | -7.59M | -5.47M | -6.21M | -5.28M | -6.12M | -6.93M |
Depreciation & Amortization | 52K | 53K | 59K | 64K | 64K | 66K | 65K | 67K | 67K | 70K | 70K | 71K | 74K | 70K | 67K | 62K | 61K |